source
- Vertex to buy Crinetics for $10 billion, expanding into endocrine disease drugsVertex announced an agreement to acquire Crinetics Pharmaceuticals for $10 billion in cash, paying $85 per share. The purchase brings two recently launched drugs for a rare hormonal disorder into…
- Oberland invests up to $400M in MeiraGTx eye gene‑therapy pipelineOberland Capital Management announced a financing package that could total $400 million to support MeiraGTx's development of gene therapies for inherited eye disorders. The arrangement includes up…